Clinical trial
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an…
NCT00303836 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00303836 |
|---|---|
| Title | Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma |
| Official title | A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes, in vitro-treated peripheral blood stem cell transplantation, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, filgrastim, aldesleukin |
| Enrollment | 58 |
| Start date | Nov 1, 2005 |
| Primary completion | Jan 1, 2007 |
| First posted | Mar 17, 2006 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: